Urination

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Retrieved on: 
금요일, 5월 3, 2024

IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 2024. These data were featured today at the Paradigm-Shifting, Practice-Changing Clinical Trials in Urology Plenary Session as an oral presentation (Abstract #24-11358) by Dr. Mark D. Tyson, Urologic Oncologist at Mayo Clinic, at the 2024 American Urological Association (AUA) Annual Meeting, in San Antonio, TX. In addition, cretostimogene has shown durable responses over time with twenty-nine patients maintaining a complete response for 12 months or more, pending evaluation and assessment of ongoing responses in twenty-two patients as of the data cutoff. Median duration of response (DOR) was not reached. 92.4% cystectomy-free survival was observed and none of the patients with a complete response had undergone radical cystectomy or showed nodal or metastatic progression.

Key Points: 
  • 92.4% cystectomy-free survival was observed and none of the patients with a complete response had undergone radical cystectomy or showed nodal or metastatic progression.
  • “The positive 12-month BOND-003 data presented at AUA 2024, with a notable duration of response, reinforces cretostimogene monotherapy as a potential backbone therapy in the NMIBC treatment landscape for BCG-unresponsive patients.
  • “Cretostimogene reported remarkable interim efficacy results, with over half of the patients experiencing complete responses upon repeat induction.
  • A webcast replay will be available in the investor relations section on the company's website following the completion of the call.

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Retrieved on: 
금요일, 5월 3, 2024

SAN ANTONIO, May 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today updated results from Cohort 2 of the Phase 2b SunRISe-1 study evaluating the efficacy and safety of investigational TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ, who are ineligible for, or decline, radical cystectomy. These data were featured today in a plenary session (Abstract #P2-01) at the 2024 American Urological Association Annual Meeting (AUA) taking place May 3-6, 2024, in San Antonio, Texas.

Key Points: 
  • "These results address an area of high unmet need for bladder sparing therapies in this patient population."
  • Results included an evaluation of 85 patients (median age of 71 years old: range 40-88; 32.9% with concurrent papillary disease) who received TAR-200 monotherapy.
  • The centrally confirmed complete response (CR) rate was 82.8% by urine cytology and/or biopsy (95% confidence interval [CI], 70.6-91.4).
  • Seven patients (8.2%) had Grade 3 or higher TRAEs and four patients (4.7%) had one or more serious TRAEs.

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
화요일, 3월 26, 2024

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

Urethral Dilator Market to reach $390.1 million by 2031, at a CAGR of 6.1%, says Coherent Market Insights

Retrieved on: 
월요일, 4월 8, 2024

Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.

Key Points: 
  • Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.
  • The market for urethral dilators is witnessing significant growth due to the rising prevalence of urethral strictures.
  • This has led to an increased demand for urethral dilators, which are used to widen the urethra and alleviate the symptoms of urethral strictures.
  • The growing adoption of minimally invasive procedures, such as urethral dilatation, is also contributing to the market opportunity for urethral dilators.

Urethral Dilator Market to reach $390.1 million by 2031, at a CAGR of 6.1%, says Coherent Market Insights

Retrieved on: 
월요일, 4월 8, 2024

Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.

Key Points: 
  • Another trend is the rising demand for reusable urethral dilators, driven by cost-effectiveness and environmental sustainability considerations among healthcare providers.
  • The market for urethral dilators is witnessing significant growth due to the rising prevalence of urethral strictures.
  • This has led to an increased demand for urethral dilators, which are used to widen the urethra and alleviate the symptoms of urethral strictures.
  • The growing adoption of minimally invasive procedures, such as urethral dilatation, is also contributing to the market opportunity for urethral dilators.

Olympus Announces iTind™ Treatment Milestone with Availability Through Major GPOs

Retrieved on: 
목요일, 3월 28, 2024

CENTER VALLEY, Pa., March 28, 2024 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today a milestone for its iTind™ device with its availability and greater patient access through the largest healthcare group purchasing organization (GPO) contracts in the United States.

Key Points: 
  • The iTind procedure is a minimally invasive procedure for the treatment of benign prostatic hyperplasia (BPH) or enlarged prostate.
  • The Healthcare Supply Chain Association estimates nearly all hospitals and a majority of non-acute care centers in America belong to at least one GPO.1
    "The availability of the iTind device through major GPO contracts marks an important milestone for Olympus," said Jay Sullivan, Group Vice President, Enterprise Solutions, Medical Systems Group, Olympus.
  • BPH is a common health problem for men over 50 as the risk increases with age.
  • Symptoms of BPH include frequent urination with a sense of urgency and a weak urinary stream and excessive urination at night.2

Filtering The Facts: The Urology Care Foundation Spreads Awareness for National Kidney Month

Retrieved on: 
금요일, 3월 1, 2024

BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.

Key Points: 
  • BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.
  • The kidneys also make hormones that help to keep blood pressure stable, make red blood cells and help keep bones strong.
  • Kidney health deserves equal awareness,” said Dr. Timothy Averch, chair of the Urology Care Foundation’s Kidney and Adrenal Health Committee.
  • For National Kidney Month, the Urology Care Foundation is focusing on information about kidney cancer and kidney stones:
    It is estimated that there will be over 81,000 new kidney cancer cases and over 14,000 cancer deaths in the United States in 2024.

Nordic Naturals Issues Voluntary Recall of Baby's Vitamin D3 Liquid Due to Elevated Levels of Vitamin D3

Retrieved on: 
토요일, 2월 17, 2024

WATSONVILLE, Calif., Feb. 17, 2024 (GLOBE NEWSWIRE) -- Nordic Naturals is voluntarily recalling one lot of Nordic Naturals Baby’s Vitamin D3 Liquid, 0.76 fl.

Key Points: 
  • WATSONVILLE, Calif., Feb. 17, 2024 (GLOBE NEWSWIRE) -- Nordic Naturals is voluntarily recalling one lot of Nordic Naturals Baby’s Vitamin D3 Liquid, 0.76 fl.
  • This recall is being conducted due to a manufacturing error that resulted in an elevated level of Vitamin D3 dosage or super potent dose.
  • Prolonged use of the recalled Baby’s Vitamin D3 Liquid could potentially lead to elevated vitamin D levels, resulting in vomiting, loss of appetite, increased thirst, frequent urination, and inability to thrive in infants.
  • Nordic Naturals can also be contacted directly at [email protected] or 888-294-7440, Monday – Friday, 8:00 a.m. - 5:00 p.m. PST.

Jelqing: the latest in a long history of attempts to enlarge the male member

Retrieved on: 
목요일, 2월 15, 2024

Posts advise that stretching a semi-erect penis could add up to an inch in length and girth by exploiting the body’s repair mechanisms.

Key Points: 
  • Posts advise that stretching a semi-erect penis could add up to an inch in length and girth by exploiting the body’s repair mechanisms.
  • Jelqing is just the latest in a long line of dubious penis enlargement techniques stretching (sorry) back millennia.
  • The ancient Greek method of lengthening the foreskin with a kynodesme (dog leash) seems positively mild compared with ancient Indian methods.
  • Penis pumps are also used for erectile dysfunction, but unlike some online claims, they don’t lengthen the penis.

Surgical interventions

  • Fillers are increasing in popularity, particularly hyaluronic acid (HA) injections.
  • HA is popular because it is doesn’t generate an immune response.
  • Surgery to cut the suspensory ligament anchoring the penis is the most widely accepted surgical elongation method.
  • A recent review concluded that evidence for supporting surgical procedures for penis enlargement is weak and the complications are under-reported.

Not needed, in most cases

  • A micropenis, usually diagnosed at birth, is where the penis is 2.5 standard deviations less than the average stretched penis length (2.3 to 2.5cm depending on ethnicity).
  • It is typically caused by a deficiency or imbalance of hormones such as testosterone or human chorionic gonadotropin (hCG), or genetics.
  • The female vagina is on average 2.5 to 3.8 inches deep, but lengthens during sexual arousal to accommodate a penis longer than this.
  • The female genitalia have multiple erogenous structures that can result in orgasm, so penile length isn’t the key characteristic.

A closer look at jelqing

  • The top two consist of numerous spaces that are surrounded by smooth muscle, which keeps most blood out of the spaces.
  • During an erection, the muscles relax allowing blood to flow in, filling these spaces, and enlarging penile volume.
  • While the theory sounds good, smooth muscle cells in the penis don’t respond in the same way skeletal muscle does.
  • If jelqing, or any other trend, was really that effective, we would have seen evidence of it in medical journals, and the sale of extra-large underwear would be making the headlines.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Which Test is Best? OB-GYN Lauren Streicher, M.D. Offers Expert Advice on Selecting Pregnancy Tests

Retrieved on: 
화요일, 2월 13, 2024

Lauren Streicher , M.D., OB-GYN, clinical professor at Northwestern University Feinberg School of Medicine, addresses the most common questions about purchasing pregnancy tests, providing expert insight on which test to choose.

Key Points: 
  • Lauren Streicher , M.D., OB-GYN, clinical professor at Northwestern University Feinberg School of Medicine, addresses the most common questions about purchasing pregnancy tests, providing expert insight on which test to choose.
  • “When speaking to patients, I find there is still a lot of confusion as to which at-home pregnancy test is right for them.
  • Whether actively trying to conceive or not, having access to accurate and reliable pregnancy tests can alleviate any uncertainties.”
    Dr. Streicher sheds light on the following considerations regarding purchasing at-home pregnancy tests:
    How do at-home pregnancy tests work?
  • Pregnancy tests detect human chorionic gonadotropin (hCG), the hormone produced by the placenta during pregnancy that is found in urine.